NCT03412591View on ClinicalTrials.gov

The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

January 7, 2023

Study Completion Date

January 7, 2023

Conditions
Sleep DisturbanceCravingCortisol; Hypersecretion
Interventions
DRUG

Suvorexant 20 mg

Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.

Trial Locations (1)

19567

Richard J Caron Foundation, Wernersville

All Listed Sponsors
lead

Milton S. Hershey Medical Center

OTHER

NCT03412591 - The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial | Biotech Hunter | Biotech Hunter